Produção científica

  1. Duchnowska R, Saad ED, Banaszek M, Pawłowska E, Liberek H, Cichowska-Cwalińska N, Jassem J. Patient Eligibility and Results for Brain Metastasis in Phase 3 Trials of Advanced Breast Cancer: A Scoping Review. Cancers (Basel). 2021 Oct 22;13(21):5306.
  2. Marta GN, de Souza TYT, Silva ARNSE, Pereira APA, Ferreira Neto DR, Asso RN, Degrande FAM, Nader-Marta G, da Silva MF, Gadia R, Hanna SA, Holzner B, Saad ED, Petersen MA. Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) Core. Curr Oncol 2021;28(5):3373-3383.
  3. Buyse M, Saad ED, Peron J, Chiem JC, De Backer M, Cantagallo E, Ciani O. The Net Benefit of a treatment should take the correlation between benefits and harms into account. J Clin Epidemiol 2021;137:148-158.
  4. Saad ED, Buyse M. Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. Cancers (Basel) 2020;12(11):3442.
  5. Bregni G, Sticca T, Camera S, Akin Telli T, Craciun L, Trevisi E, Pretta A, Kehagias P, Leduc S, Senti C, Deleporte A, Vandeputte C, Saad ED, et al. Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel. Acta Oncol 2020;59(12):1438-1446.
  6. Coart E, Suciu S, Squifflet P, Saad ED, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. Eur J Cancer 2020;137:171-174.
  7. Saad ED, Buyse M. Commentary on Bamat et al. Clin Trials 2020;17(5):560-561.
  8. Buyse M, Trotta L, Saad ED, Sakamoto J. Central statistical monitoring of investigator-led clinical trials in oncology. Int J Clin Oncol 2020;25(7):1207-1214.
  9. Saad ED, Buyse M. Statistical aspects in adjuvant and neoadjuvant trials for gastrointestinal cancer in 2020: focus on time-to-event endpoints. Curr Opin Oncol 2020;32(4):384-390.
  10. Burzykowski T, Coart E, Saad ED, et al. JAMA Netw Open 2019;2(9):e1911750.
  11. Rutkowski J, Saad ED, Burzykowski T, Buyse M, Jassem J. Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC. J Thorac Oncol 2019;14(9):1619-1627.
  12. Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol 2019;20(3):361-370.
  13. Saad ED, Tannock IF. Avoiding the hazards of misinterpreting treatment effects. Ann Oncol 2019;30(1):16-18.
  14. Buyse M, Burzykowski T, Saad ED. The search for surrogate endpoints for immunotherapy trials. Ann Transl Med 2018 Jun;6(11):231.
  15. Saad ED, Zalcberg JR, Péron J, Coart E, Burzykowski T, Buyse M. Understanding and Communicating Measures of Treatment Effect on Survival: Can We Do Better? J Natl Cancer Inst 2018;110(3):232-240.
  16. Riechelmann RP, Péron J, Seruga B, Saad ED. Meta-Research on Oncology Trials: A Toolkit for Researchers with Limited Resources. Oncologist 2018; 23(12):1467-1473.
  17. Saad ED, Buyse M. Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy. Ann Oncol 2017;28(11):2629-2630.
  18. Buyse M, Squifflet P, Coart E, Quinaux E, Punt CJ, Saad ED. The impact of data errors on the outcome of randomized clinical trials. Clin Trials 2017;14(5):499-506.
  19. Michiels S, Saad ED, Buyse M. Authors' Reply to Schoenfeld: "Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors". Drugs 2017;77(10):1139-1140.
  20. Reinert T, Saad ED, Barrios CH, Bines J. Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer. Front Oncol 2017;7:26.
  21. Michiels S, Saad ED, Buyse M. Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. Drugs 2017;77(7):713-719.
  22. Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to Review the Role of Surrogate End Points in Health Policy: State of the Art and the Way Forward. Value Health 2017;20(3):487-495.
  23. Marta GN, Saad ED. Assessment of quality of life in phase III trials of radiotherapy in localized or locally advanced head and neck cancer over the past 17 years. Ann Palliat Med 2017;6(1):73-80.
  24. Saad ED, Paoletti X, Burzykowski T, Buyse M. Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol 2017; 14:317-323.
  25. Burzykowski T, Saad ED, Buyse M. Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question. JAMA Oncol 2016 Nov 17. doi: 10.1001/jamaoncol.2016.3941. [Epub ahead of print]
  26. Buyse M, Saad ED, Burzykowski T. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 2016;375:1591-2.
  27. Adamowicz K, Saad ED, Jassem J. Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer. Cancer Treat Rev 2016;50:194-199.
  28. Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework. Nat Rev Drug Discov 2016 Jul;15(7):516.
  29. Saad ED, Buyse M. Response to the letter to the editor 'Reply to "Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents" by H. K. van Halteren'. Ann Oncol 2016 Aug;27(8):1653.
  30. Buyse M, Burzykowski T, Saad ED. Neoadjuvant as Future for Drug Development in Breast Cancer--Letter. Clin Cancer Res 2016 Jan 1;22(1):268.
  31. Saad ED, Buyse M. Statistical Controversies in Clinical Research: Endpoints Other than Overall Survival Are Vital for Regulatory Approval of Anticancer Agents. Ann Oncol 2015 Nov 16 [Epub ahead of print]
  32. Squifflet P, Michiels S, Siegel D, Vij R, Jagannath S, Saad ED, Rajangam K, Ro SK, Buyse M. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk2015;15:680-6.
  33. de Araujo Toloi D, Critchi G, Mangabeira A, Matsushita F, Riechelmann RP, Hoff PM, Saad ED. Living better or living longer? Perceptions of patients and health care professionals in oncology. Ecancermedicalscience 2015;9:574.
  34. Panico FF, Troster EJ, Oliveira CS, Faria A, Lucena M, João PR, Saad ED, Foronda FA, Delgado AF, de Carvalho WB. Risk Factors for Mortality and Outcomes in Pediatric Acute Lung Injury/Acute Respiratory Distress Syndrome. Pediatr Crit Care Med2015;16:e194-200.
  35. Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K, Taylor RS. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol 2015 Mar 6. pii: S0895-4356(15)00113-4.
  36. Arap MA, Reis RB, Torricelli FC, Masson AL, Saad ED. Brazilian Abstracts Presented at the American Urological Association Annual Meetings: Contribution, Publication Rates, and Comparison with Oncology Abstracts. Int Braz J Urol 2014;40:730-737.
  37. Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M, Taylor RS. Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. Int J Technol Assess Health Care 2014;30:312-24.
  38. Marta GN, Del Nero LG, Marta GN, Mangabeira A, Critchi G, Kovács MJ, Silva JL, Saad ED. Treatment priorities in oncology: do we want to live longer or better? Clinics (Sao Paulo) 2014;69:509-514.
  39. Bines J, Earl H, Buzaid AC, Saad ED. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter? Ann Oncol 2014;25(6):1079-85.
  40. Bariani GM, de Celis Ferrari AC, Precivale M, Arai R, Saad ED, Riechelmann RP. Sample Size Calculation in Oncology Trials: Quality of Reporting and Implications for Clinical Cancer Research. Am J Clin Oncol 2014 Jan 7 [Epub ahead of print].
  41. Saad ED, Sasse EC, Borghesi G, Miranda VC, Fede AB, Saad LS, Oliveira V, Barros EA, Pascoin M, Del Giglio A, Riechelmann R. Formal statistical testing and inference in randomized phase II trials in medical oncology. Am J Clin Oncol 2013;36:143-5.
  42. Saad ED, Buyse M. Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects. Acta Oncol 2012;51:890-6.
  43. Saad ED, Adamowicz K, Katz A, Jassem J. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials. Cancer Treat Rev 2012;38:807-14.
  44. Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 2012;30:1750-4.
  45. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, Gansl RC. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer 2012;11:93-100.
  46. Adamowicz K, Jassem J, Katz A, Saad ED. Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. Cancer Treat Rev 2012;38:554-8.
  47. Saad ED. Endpoints in advanced breast cancer: methodological aspects & clinical implications. Indian J Med Res 2011;134:413-8.
  48. Buyse M, Sargent D, Saad ED. Survival Is Not a Good Outcome for Randomized Trials With Effective Subsequent Therapies. J Clin Oncol 2011;29:4719-20.
  49. De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, Bueno-Da-Silva AEB, Zago MA, Zanichelli MA, Abdelhay E, Castro FA, Jacysyn JF, Amarante-Mendes GP. BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients. Oncogene 2011;30:223-33.
  50. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010;28:1958-62.
  51. Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 2010;21:7-12.
  52. Bacchi CE, Prisco F, Carvalho FM, Ojopi EB, Saad ED. Potential economic impact of the 21-gene expression assay on the treatment of breast cancer in Brazil. Rev Assoc Med Bras 2010;56:186-91.
  53. Saad ED, Reis PT, Borghesi G, Machado MC, Simon SD, Tabacof J, Gansl RC. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer. Rev Assoc Med Bras 2010;56:22-6.
  54. Saad ED, Mangabeira A, Masson AL, Prisco FE. The geography of clinical cancer research: analysis of abstracts presented at the American Society of Clinical Oncology Annual Meetings. Ann Oncol 2010;21:627-32.
  55. Fonseca M, Araújo GT, Saad ED. Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras 2009;55:410-5.
  56. Katz A, Calabrich A, Saad ED. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med2009;360:2367-8.
  57. Katz A, Saad ED. CALGB 9633: an underpowered trial with a methodologically questionable conclusion. J Clin Oncol2009;27:2300-1.
  58. Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. Ann Oncol 2009;20:460-4.
  59. Saad ED, Pinheiro CM, Masson AL, Borghesi G, Hoff PM, Prisco FE. Increasing output and low publication rate of Brazilian studies presented at the American Society of Clinical Oncology Annual Meetings. Clinics (Sao Paulo) 2008;63:293-6.
  60. Brumatti G, Yon M, Castro FA, Bueno-da-Silva AE, Jacysyn JF, Brunner T, Amarante-Mendes GP. Conversion of CD95 (Fas) Type II into Type I signaling by sub-lethal doses of cycloheximide. Exp Cell Res 2008;314(3):554-63.
  61. Masson AL, Mangabeira A, Bueno-da-Silva AEB, Saad ED. Assessment of the Brazilian Scientific Production Based on papers selected for the ASCO annual meetings: where are we going? Revista Brasileira de Oncologia Clínica 2008, number 15.
  62. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007;99:592-600.
  63. Katz A, Saad ED, Porter P, Pusztai L. Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol2007;8:55-62.
  64. Riechelmann RP, Saad ED. A systematic review on drug interactions in oncology. Cancer Invest 2006;24:704-12.
  65. Machado-Netto MC, Lacerda EC, Heinke T, Maia DC, Lowen MS, Saad ED. Massive orbital metastasis of hepatocellular carcinoma. Clinics (Sao Paulo) 2006;61:359-62.
  66. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 2005;56:286-90.
  67. Saad ED, Hoff PM. Chemotherapy of Metastatic Colorectal Cancer. Curr Treat Options Gastroenterol 2005; 8:239-247.
  68. Castro FA, Jacysyn JF, Bueno-da-Silva AEB, Hamerschlak N, Amarante-Mendes GP. Apoptosis resistance in chronic myelogenous leukemia. Revista Einstein 2005;3:207-12.
  69. Saad ED, Hoff PM. Molecular-targeted agents in pancreatic cancer. Cancer Control 2004; 11:32-8.
  70. Silva SO, Rodrigues MR, Ximenes VF, Bueno-da-Silva AEB, Amarante-Mendes GP, Campa A. Neutrophils as a specific target for melatonin and kynuramines effects on cytokine release. J Neuroimmunol 2004;156:146-52.
  71. Ramos MG, Rabelo FL, Brumatti G, Bueno-da-Silva AEB, Amarante-Mendes GP, Alvarez-Leite JL. Butyrate increases apoptosis induced by different antineoplastic drugs in monocytic leukemia cells. Chemotherapy 2004;50:221-8.
  72. Hoff PM, Saad ED, Pazdur R, et al. Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. Invest New Drugs 2004; 22:307-13.
  73. Hoff PM, Saad ED, Ajani JA, et al: Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. Clin Cancer Res 2003;9:134-42.
  74. Rotea W Jr, Saad ED. Targeted drugs in oncology: new names, new mechanisms, new paradigm. Am J Health Syst Pharm2003;60:1233-43.
  75. Saad ED, Hoff PM. UFT and oral leucovorin as radiation sensitizers in rectal and other gastrointestinal malignancies. Cancer Invest 2003;21(4):624-9.
  76. Bueno-da-Silva AEB, Brumatti G, Russo FO, Green DR, Amarante-Mendes, GP. Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity. Cell Death and Differ 2003;10:592-8.
  77. Saad ED, Abbruzzese JL. Prognostic stratification in UPC: a role for assessing the value of conventional dose and high-dose chemotherapy for unknown primary carcinoma. Crit Rev Hematol Oncol 2002;41:205-11.
  78. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002;20:3-10.
  79. Saad ED, Hoff PM, Carnelós R, et al. Critérios comuns de toxicidade do Instituto Nacional de Câncer do Estados Unidos. Common toxicity criteria of the National Cancer Institute. Rev Bras Cancerol 2002;48:63-96.
  80. Saad ED, Kraut EH, Hoff PM, et al. Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol 2002;25:451-3.
  81. Saad ED, Machado MC, Wajsbrot D, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 2002;32:35-41.
  82. Saad ED, Hoff PM. Other fluorinated pyrimidines in the treatment of solid tumors. Oncology (Huntingt) 2001;15(1 suppl 2):65-8.
  83. Elasmar SA, Saad ED, Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jpn J Clin Oncol2001;31:172-4.
  84. Hoff PM, Saad ED, Ravandi-Kashani F, et al. Phase I trial of i.v. administered tirapazamine plus cyclophosphamide. Anticancer Drugs 2001;12:499-503.
  85. Saad ED, Thomas DA, O´Brien S, et al. Progressive multifocal leukoencephalopathy with concurrent Richter´s syndrome. Leuk Lymphoma 2000;38:183-90.
  86. Hoff PM, Janjan NA, Saad ED, et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol 2000;18:3529-34.
  87. Hoff PM, Saad ED, Janjan NA, et al. A phase I study. Preoperative UFT/leucovorin and radiation therapy in rectal cancer. Oncology (Huntingt) 2000;14(10 suppl 9):56-8.
  88. Saad ED, Grunspun H. Medicina baseada em evidências. Rev Hosp Clin Fac Med S Paulo 1996;51:34-6.